| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| EPIK-B5 | 21-32 | HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation who progressed or relapsed on or after treatment with an AI plus a CDK4/6 inhibitor. |
The purpose of this study is to obtain more comprehensive data on the efficacy and safety of alpelisib (BYL719) in combination with fulvestrant compared with placebo plus fulvestrant in men or postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation who progressed or relapsed on or after treatment with an AI plus a CDK4/6 inhibitor. |
DSSG Group: Breast
Proteomics / Molecular Breast
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Proteomics / Molecular Breast | 09-07 | Breast cancer |
The purpose of this trial is to examine the function of different genes and proteins, previously identified to be of interest, and identify new ones, as well as the means by which they interact and differ between cancer cells. |